An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Trial Status: active
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for
participants with solid tumors that are expressing a protein called nectin-4.
The main questions it aims to answer are:
What is the the safe and effective dose of CRB-701 when used alone? What cancers can be
treated effectively with CRB-701?
Participants will be asked to attend clinic and be given a intravenous infusion of
CRB-701 on its own. They will have blood tests and other assessments to measure whether
CRB-701 will have CT or MRI scans to measure the effect on tumors.
Inclusion Criteria
Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit.
Exclusion Criteria
Active of uncontrolled CNS metastases
History of solid tumors other than the diseases under study
History of and/or current cardiovascular events or conditions in the previous 6 months
